Dyne Therapeutics. has been granted a patent for a complex that links an anti-transferrin receptor antibody to a modified oligonucleotide. This complex targets muscle cells and may inhibit DUX4 expression, with potential applications in treating muscle-related disorders. The oligonucleotide features specific modifications for enhanced efficacy. GlobalData’s report on Dyne Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dyne Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Dyne Therapeutics's grant share as of July 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
Muscle-targeting complexes with modified oligonucleotides for therapy
The patent US12018087B2 describes a novel complex that consists of an anti-transferrin receptor antibody covalently linked to an oligonucleotide. The antibody specifically targets the human transferrin receptor protein 1 (TfR1) within a defined amino acid range (C89 to F760) but does not bind to the transferrin binding site. The oligonucleotide, which ranges from 15 to 30 nucleotides in length, includes modifications such as 2'-modified nucleosides and may feature a phosphorothioate backbone. The claims detail various configurations of the oligonucleotide, including specific lengths of complementary regions and the presence of gap regions flanked by modified nucleosides.
Additionally, the patent outlines methods for delivering the oligonucleotide to subjects, particularly those with muscular dystrophies, including myotonic dystrophy type I. The delivery method involves intravenous administration of the complex, targeting muscle cells such as skeletal, cardiac, or smooth muscle cells. The complex can also incorporate a cleavable linker for enhanced delivery, and the antibody can exist in various forms, including Fab fragments. Overall, the patent presents a targeted approach for oligonucleotide delivery, potentially advancing therapeutic strategies for muscle-related disorders.
To know more about GlobalData’s detailed insights on Dyne Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
